Search research articles
Contact Us
Filters
Showing results (31-40 of 83) with videos related to
Page
of 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study
Didier Decaudin, Nicolas Mounier, Hervé Tilly, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 30, 2004
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma
Olivier Hermine, Hervé Dombret, Joel Poupon, et al.
Clinical Pharmacokinetics
|
July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
Ken Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Retrovirology
|
March 23, 2020
Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) as a maintenance therapy for adult T cell leukemia/lymphoma
Ambroise Marçais, Lucy Cook, Aviva Witkover, et al.
Hematological Oncology
|
June 30, 2016
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma
Colombe Saillard, Helene Guermouche, Coralie Derrieux, et al.
Haematologica
|
June 12, 2013
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, et al.
Blood
|
June 4, 2005
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases
Fadi Fakhouri, Jean-Paul Vernant, Agnès Veyradier, et al.
Haematologica
|
February 29, 2012
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA
Marie-Hélène Delfau-Larue, Laurence de Leval, Bertrand Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
Emmanuel Bachy, Pauline Brice, Richard Delarue, et al.
Genes, Chromosomes & Cancer
|
November 20, 2013
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index
Clémentine Sarkozy, Christine Terré, Fabrice Jardin, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 83) with videos related to
Sort By:
Page
of 9
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study
Didier Decaudin, Nicolas Mounier, Hervé Tilly, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 30, 2004
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma
Olivier Hermine, Hervé Dombret, Joel Poupon, et al.
Clinical Pharmacokinetics
|
July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
Ken Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Retrovirology
|
March 23, 2020
Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) as a maintenance therapy for adult T cell leukemia/lymphoma
Ambroise Marçais, Lucy Cook, Aviva Witkover, et al.
Hematological Oncology
|
June 30, 2016
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma
Colombe Saillard, Helene Guermouche, Coralie Derrieux, et al.
Haematologica
|
June 12, 2013
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, et al.
Blood
|
June 4, 2005
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases
Fadi Fakhouri, Jean-Paul Vernant, Agnès Veyradier, et al.
Haematologica
|
February 29, 2012
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA
Marie-Hélène Delfau-Larue, Laurence de Leval, Bertrand Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
Emmanuel Bachy, Pauline Brice, Richard Delarue, et al.
Genes, Chromosomes & Cancer
|
November 20, 2013
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index
Clémentine Sarkozy, Christine Terré, Fabrice Jardin, et al.
Page
of 9